All Type of News
Domestic pharmaceutical companies win Trajenta’s crystalline patent nullification trial
Domestic pharmaceutical companies have won the crystalline patent nullification trial of ‘Trajenta,’ a new DPP-4 type antidiabetic.
Including Trajenta Duo, Trajenta imported by Boehringer and sold by Yuhan Corporatio...
Listed pharmaceuticals’ sales promotion activities weakened by MERS and ethical management
As the listed pharmaceutical companies’ sales promotion activities have been weakened due to the spread of MERS and ethical management, their expenses related were also analyzed to be reduced.
According to the Yakup ...
Multinational pharmaceutical tightening promotion standards
Foreign pharmaceutical companies have strengthened their promotion activity standards higher than what it is in the industry. They are basically showing their will to get away from any suspicion while domestic pharmac...
Will Sovaldi and Harvoni pass the first gateway for insurance benefit?
The health insurance benefit evaluation scheme of the Gilead’s hepatitis C treatments, Sovaldi(sofosbuvir) and Harvoni(sofosbuvir, ledipasvir) will finally be proposed at the Drug Benefit Deliberation Committee, Healt...
Alexion Korea selects Wolman disease treatment as first drug to introduceAlexion, a U.S. rare disease pharmaceutical company getting ready for its Korean branch, has decided the first pharmaceutical product to introduce in the domestic market.
It is...
|
Price dualization for NIP cervical cancer vaccines
Cervical cancer vaccines for the National Immunization Program(NIP) which will be conducted from this June are expected to be decided at dualized prices.
According to the pharmaceutical industry, it was told the Kore...
Pharmaceutical association’s extreme action to reveal rebate-suspicious companies
The Korea Pharmaceutical Manufacturers Association has decided to reveal the ‘Secrete Rebate Survey’ result at a board meeting on the 22nd.
The reveal will be made internally, not outside. Although a part of the indu...
Treatment spent the most R&D expenses, ‘tumor treatment’
A treatment spent the most R&D expenses by pharmaceutical companies was known to be tumor treatments.
The Korea Health Industry Development Institute recently unveiled the information through the ‘2014 Pharmaceutical...
Slowly changing metal illness treatments
Mental illness treatments introduced in Korea have experienced relatively minor changes compared to other diseases. It is also a problem for people to avoid getting treated as having prejudices and misunderstandings t...
Will ‘probiotics’ become hot in the market?
While a series of probiotics products have been launched in the pharmaceutical industry, the healthcare authorities started to prove their safety.
Recently, it was confirmed by a cover result that the Ministry of Foo...
